Status: Not yet recruiting
A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
To Evaluate the Efficacy and Safety of TQB3909 Tablets versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Participants needed: 128
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Updated: Aug 11, 2026Locations: 2
Eligibility criteria
The subject voluntarily agrees to participate in this study, signs the informed... [+7]
History of or concurrent other malignancies within 3 years prior to the first do... [+18]